IL187966A0 - New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases - Google Patents
New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseasesInfo
- Publication number
- IL187966A0 IL187966A0 IL187966A IL18796607A IL187966A0 IL 187966 A0 IL187966 A0 IL 187966A0 IL 187966 A IL187966 A IL 187966A IL 18796607 A IL18796607 A IL 18796607A IL 187966 A0 IL187966 A0 IL 187966A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- receptor antagonists
- gastrointestinal diseases
- neurokinin receptor
- azetidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0501494 | 2005-06-23 | ||
| PCT/SE2006/000759 WO2006137790A1 (en) | 2005-06-23 | 2006-06-21 | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL187966A0 true IL187966A0 (en) | 2008-03-20 |
Family
ID=37570728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL187966A IL187966A0 (en) | 2005-06-23 | 2007-12-06 | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100069346A1 (en) |
| EP (1) | EP1899326A4 (en) |
| JP (1) | JP2009501144A (en) |
| KR (1) | KR20080036957A (en) |
| CN (1) | CN101203511A (en) |
| AU (1) | AU2006259891A1 (en) |
| CA (1) | CA2612133A1 (en) |
| IL (1) | IL187966A0 (en) |
| MX (1) | MX2007015606A (en) |
| NO (1) | NO20080445L (en) |
| WO (1) | WO2006137790A1 (en) |
| ZA (1) | ZA200710611B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057828A1 (en) * | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | COMPOUNDS DERIVED FROM AZETIDINE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION |
| WO2007136326A2 (en) * | 2006-05-18 | 2007-11-29 | Astrazeneca Ab | ) t e text as een esta s e y t s ut o ty to rea as o ows: 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 3 |
| WO2007136325A1 (en) * | 2006-05-18 | 2007-11-29 | Astrazeneca Ab | 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 2 |
| US8106208B2 (en) * | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| EP2125711B1 (en) * | 2007-03-08 | 2013-11-06 | Albireo Ab | 3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease |
| WO2008118092A1 (en) * | 2007-03-28 | 2008-10-02 | Albireo Ab | Maleate salt of 3-bromo-n-{ (2s) -2- (4-f luorophenyl) -4- [3- (4-acetylpiperazin-1-yl) azetidin-1-yl] butyl} -methyl-5- (trifluoromethyl)benzamide for the treatment of gastrointestinal disorders |
| WO2008118091A1 (en) * | 2007-03-28 | 2008-10-02 | Albireo Ab | A fumarate salt of 3-bromo-n-{ (2s) -2- (4 -fluorophenyl) -4- [3- (4-acetylpiperazin-l-yl) azetidin-1-yl] butyl} -n-methyl-5- (trifluoromethyl)benzamide for the treatment of gastrointestinal disorders |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| CN102459240A (en) * | 2009-04-22 | 2012-05-16 | 詹森药业有限公司 | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| AR080056A1 (en) | 2010-02-01 | 2012-03-07 | Novartis Ag | CICLOHEXIL-AMIDA DERIVATIVES AS ANTAGONISTS OF CRF RECEIVERS |
| JP2013518085A (en) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | Pyrazolo [5,1b] oxazole derivatives as CRF-1 receptor antagonists |
| JP5748777B2 (en) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Cyclohexylamide derivatives as CRF receptor antagonists |
| CN105663133B (en) * | 2016-03-07 | 2019-06-25 | 青岛市肿瘤医院 | A kind of pharmaceutical composition and its application inhibiting lymphoma cell proliferation |
| MX2021014271A (en) | 2019-05-24 | 2022-01-06 | Integrative Res Laboratories Sweden Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfo nylphenoxy)ethyl](propyl)amine and uses thereof. |
| WO2022101227A1 (en) | 2020-11-10 | 2022-05-19 | Integrative Research Laboratories Sweden Ab | [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine (mesdopetam) for use in the prevention or reduction of sensitization to a pharmaceutical drug for parkinson's disease, in particular l-dopa induced dyskinesias |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
| GB9601202D0 (en) * | 1996-01-22 | 1996-03-20 | Pfizer Ltd | Piperidones |
| JP2002520316A (en) * | 1998-07-10 | 2002-07-09 | アストラゼネカ・アクチエボラーグ | N-substituted naphthalenecarboxamides as neurokinin receptor antagonists |
| GB9922519D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
| TW200508221A (en) * | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
-
2006
- 2006-06-21 US US11/993,361 patent/US20100069346A1/en not_active Abandoned
- 2006-06-21 EP EP06747948A patent/EP1899326A4/en not_active Withdrawn
- 2006-06-21 CA CA002612133A patent/CA2612133A1/en not_active Abandoned
- 2006-06-21 JP JP2008518081A patent/JP2009501144A/en not_active Abandoned
- 2006-06-21 MX MX2007015606A patent/MX2007015606A/en not_active Application Discontinuation
- 2006-06-21 CN CNA2006800226798A patent/CN101203511A/en active Pending
- 2006-06-21 WO PCT/SE2006/000759 patent/WO2006137790A1/en active Application Filing
- 2006-06-21 KR KR1020077030086A patent/KR20080036957A/en not_active Application Discontinuation
- 2006-06-21 AU AU2006259891A patent/AU2006259891A1/en not_active Abandoned
-
2007
- 2007-12-05 ZA ZA200710611A patent/ZA200710611B/en unknown
- 2007-12-06 IL IL187966A patent/IL187966A0/en unknown
-
2008
- 2008-01-23 NO NO20080445A patent/NO20080445L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20100069346A1 (en) | 2010-03-18 |
| ZA200710611B (en) | 2008-11-26 |
| EP1899326A4 (en) | 2009-12-16 |
| WO2006137790A1 (en) | 2006-12-28 |
| KR20080036957A (en) | 2008-04-29 |
| CA2612133A1 (en) | 2006-12-28 |
| MX2007015606A (en) | 2008-02-25 |
| JP2009501144A (en) | 2009-01-15 |
| EP1899326A1 (en) | 2008-03-19 |
| CN101203511A (en) | 2008-06-18 |
| NO20080445L (en) | 2008-01-23 |
| AU2006259891A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200710611B (en) | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases | |
| EP1899318A4 (en) | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases | |
| ZA200707498B (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
| IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
| IL195571A0 (en) | Compounds for the treatment of periodontal disease | |
| ZA200808178B (en) | Imidazolothiazole compounds for the treatment of disease | |
| TWI369987B (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
| IL191283A (en) | Compositions for the treatment of ophthalmic disorders | |
| ZA200706791B (en) | Isoxazole combretasin derivatives for the treatment of disorders | |
| EP1833467A4 (en) | Pharmaceutical compositions for sleep disorders | |
| ZA200800320B (en) | Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists | |
| IL180680A0 (en) | Piperazine derivatives useful for the treatment of gastrointestinal disorders | |
| IL186188A0 (en) | Pyrimidindione derivatives as prokineticin 2 receptor antagonists | |
| HK1119577A1 (en) | Compounds for the treatment of metabolic disorders | |
| EP1959959A4 (en) | Morpholine carboxamide prokineticin receptor antagonists | |
| ZA200801667B (en) | Novel pharmaceutical combinations for the treatment of respiratory disorders | |
| PT2418201E (en) | Polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin) yl]-4-penten-2-amine p-hydroxybenzoate for the treatment of central nervous system disorders | |
| ZA200805761B (en) | Pharmaceutical composition for the treatment of nail disease | |
| IL188856A0 (en) | Novel piperidine derivatives as chemokine receptor modulators useful for the treatment of respiratory diseases | |
| ZA200805159B (en) | Imidazole derivatives for the treatment of gastrointestinal disorders | |
| SI1833821T1 (en) | Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases | |
| ZA200802339B (en) | Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists | |
| HU0500145D0 (en) | Composition for the treatment of oral diseases | |
| ZA200900613B (en) | 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonist for the treatment of CNS disorders | |
| IL185640A0 (en) | Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists |